2018 Hypertrophic Cardiomyopathy Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Hypertrophic Cardiomyopathy Market
Hypertrophic cardiomyopathy (HCM) is an inherited genetic disorder in which the heart walls thicken. The thickening can affect the heart’s pumping power as it does not relax adequate enough to fill the heart with blood. Mutation in one of the genes causes sarcomeres, a structural unit of muscles, to become disorganized and thicker. Hypertrophic Cardiomyopathy affects around one in 500 people in the US. Fainting, breath shortage, chest pains and occasionally cardiac arrest are the symptoms of HCM.
The market size of Hypertrophic cardiomyopahty is estimated to be around $1 billion, encouraging 10+ companies to currently participate in development of therapeutic compounds for the Hypertrophic cardiomyopahty.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Hypertrophic Cardiomyopathy pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Hypertrophic Cardiomyopathy pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hypertrophic Cardiomyopathy pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
The market size of Hypertrophic cardiomyopahty is estimated to be around $1 billion, encouraging 10+ companies to currently participate in development of therapeutic compounds for the Hypertrophic cardiomyopahty.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Hypertrophic Cardiomyopathy pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Hypertrophic Cardiomyopathy pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hypertrophic Cardiomyopathy pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 HYPERTROPHIC CARDIOMYOPATHY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hypertrophic Cardiomyopathy Pipeline Snapshot
2.3 Hypertrophic Cardiomyopathy Pipeline by Phase
2.4 Hypertrophic Cardiomyopathy Pipeline by Company
2.5 Hypertrophic Cardiomyopathy Pipeline by Mechanism of Action
3 HYPERTROPHIC CARDIOMYOPATHY- COMPANY WISE PIPELINE ANALYSIS
Miragen Therapeutics Inc.
MyoKardia Inc.
4 HYPERTROPHIC CARDIOMYOPATHY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HYPERTROPHIC CARDIOMYOPATHY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 HYPERTROPHIC CARDIOMYOPATHY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hypertrophic Cardiomyopathy Pipeline Snapshot
2.3 Hypertrophic Cardiomyopathy Pipeline by Phase
2.4 Hypertrophic Cardiomyopathy Pipeline by Company
2.5 Hypertrophic Cardiomyopathy Pipeline by Mechanism of Action
3 HYPERTROPHIC CARDIOMYOPATHY- COMPANY WISE PIPELINE ANALYSIS
Miragen Therapeutics Inc.
MyoKardia Inc.
4 HYPERTROPHIC CARDIOMYOPATHY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HYPERTROPHIC CARDIOMYOPATHY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Hypertrophic Cardiomyopathy Pipeline by Phase, H2- 2018
Figure 2: Hypertrophic Cardiomyopathy Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Hypertrophic Cardiomyopathy Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Hypertrophic Cardiomyopathy Pipeline by Phase, H2- 2018
Figure 2: Hypertrophic Cardiomyopathy Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Hypertrophic Cardiomyopathy Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Hypertrophic Cardiomyopathy Pipeline by Phase, H2- 2018
Hypertrophic Cardiomyopathy Pipeline by Companies, H2- 2018
Hypertrophic Cardiomyopathy Pipeline by Mechanism of Action, H2- 2018
Table 1: Miragen Therapeutics Inc. Hypertrophic Cardiomyopathy Pipeline Drugs, H2- 2018
Table 2: MyoKardia Inc. Hypertrophic Cardiomyopathy Pipeline Drugs, H2- 2018
Hypertrophic Cardiomyopathy Pipeline by Phase, H2- 2018
Hypertrophic Cardiomyopathy Pipeline by Companies, H2- 2018
Hypertrophic Cardiomyopathy Pipeline by Mechanism of Action, H2- 2018
Table 1: Miragen Therapeutics Inc. Hypertrophic Cardiomyopathy Pipeline Drugs, H2- 2018
Table 2: MyoKardia Inc. Hypertrophic Cardiomyopathy Pipeline Drugs, H2- 2018
